Literature DB >> 31332506

The contribution of cerebrovascular risk factors, metabolic and inflammatory changes to cognitive decline in Parkinson's disease: preliminary observations.

Branislav Veselý1,2, Eva Koriťáková2,3, Nicolaas I Bohnen4, Daša Viszlayová5, Silvia Királová6, Peter Valkovič7, Egon Kurča8, Ivan Rektor9.   

Abstract

To determine whether systemic medical factors, such as vascular risk factors, metabolic and inflammatory markers contribute to cognitive decline in Parkinson's disease (PD); if confirmed to determine whether a clinically applicable risk factor model can predict the conversion from normal cognition (NC) to mild cognitive impairment (MCI). 58 patients who met the UK Brain Bank Criteria for PD underwent clinical and laboratory assessment at study entry; 47 patients were re-assessed after 2 years. Medical history, vascular risk (QRISK2), blood metabolic and inflammatory factors, brain vessel examinations, activity of daily living, and neuropsychological testing were performed. Forty patients had NC and 18 patients had MCI at baseline. Patients with MCI had higher level of interleukin 6, folic acid below normal range and higher L-dopa equivalent dose compared to cognitive normal patients at baseline. Patients with NC at baseline were classified into two groups: patients who remained cognitively normal (non-converters, n = 23) and patients who progressed to MCI (converters, n = 11). MCI converters were older at baseline and had higher QRISK2 than the non-converters. Patients with higher QRISK2, lower uric acid level and lower activity of daily living scale at baseline had a higher risk of converting from NC to MCI with a sensitivity of 72.2%, a specificity of 87%, and an overall accuracy of 82.4%. Systemic medical factors are associated with cognitive impairment in PD both cross-sectionally and longitudinally. A risk factor model predicting the decline from NC to MCI could be constructed.

Entities:  

Keywords:  Cognitive impairment; Inflammation; Metabolic factors; Parkinson’s disease; Vascular risk factors

Year:  2019        PMID: 31332506      PMCID: PMC6959128          DOI: 10.1007/s00702-019-02043-7

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  28 in total

1.  "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician.

Authors:  M F Folstein; S E Folstein; P R McHugh
Journal:  J Psychiatr Res       Date:  1975-11       Impact factor: 4.791

2.  FUNCTIONAL EVALUATION: THE BARTHEL INDEX.

Authors:  F I MAHONEY; D W BARTHEL
Journal:  Md State Med J       Date:  1965-02

3.  Association of cognitive impairment with plasma levels of folate, vitamin B12 and homocysteine in the elderly.

Authors:  Nikolaos Dimopoulos; Christina Piperi; Aristea Salonicioti; Vassiliki Psarra; Flerri Gazi; Charalambos Nounopoulos; Robert W Lea; Anastasios Kalofoutis
Journal:  In Vivo       Date:  2006 Nov-Dec       Impact factor: 2.155

4.  Serum inflammatory biomarkers in Parkinson's disease.

Authors:  M Dufek; M Hamanová; J Lokaj; D Goldemund; I Rektorová; Z Michálková; K Sheardová; I Rektor
Journal:  Parkinsonism Relat Disord       Date:  2008-07-30       Impact factor: 4.891

5.  Vascular pathology in patients with idiopathic Parkinson's disease.

Authors:  Ivan Rektor; David Goldemund; Katerina Sheardová; Irena Rektorová; Zuzana Michálková; Michal Dufek
Journal:  Parkinsonism Relat Disord       Date:  2008-04-09       Impact factor: 4.891

Review 6.  Role of complement in neurodegeneration and neuroinflammation.

Authors:  Domenico Marco Bonifati; Uday Kishore
Journal:  Mol Immunol       Date:  2006-05-15       Impact factor: 4.407

7.  UPDRS activity of daily living score as a marker of Parkinson's disease progression.

Authors:  Madaline B Harrison; Scott A Wylie; Robert C Frysinger; James T Patrie; Diane S Huss; Lillian J Currie; G Frederick Wooten
Journal:  Mov Disord       Date:  2009-01-30       Impact factor: 10.338

Review 8.  Uric acid in Parkinson's disease.

Authors:  Ilana Schlesinger; Naomi Schlesinger
Journal:  Mov Disord       Date:  2008-09-15       Impact factor: 10.338

Review 9.  The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations.

Authors: 
Journal:  Mov Disord       Date:  2003-07       Impact factor: 10.338

10.  Uric acid associates with cognition in Parkinson's disease.

Authors:  Tua Annanmaki; Anniina Pessala-Driver; Laura Hokkanen; Kari Murros
Journal:  Parkinsonism Relat Disord       Date:  2008-03-05       Impact factor: 4.891

View more
  5 in total

Review 1.  Blood and Cerebrospinal Fluid Biomarkers of Inflammation in Parkinson's Disease.

Authors:  Milan Zimmermann; Kathrin Brockmann
Journal:  J Parkinsons Dis       Date:  2022       Impact factor: 5.520

2.  Relationship between Uric Acid Level and Severity of Acute Primary Cerebral Infarction: A Cross-Sectional Study.

Authors:  Ruying Wang; Yi Zhong; Quan Zhou; Ping Xu
Journal:  Biomed Res Int       Date:  2020-06-22       Impact factor: 3.411

Review 3.  Experimental Models of Cognitive Impairment for Use in Parkinson's Disease Research: The Distance Between Reality and Ideal.

Authors:  Yaohua Fan; Jiajun Han; Lijun Zhao; Chunxiao Wu; Peipei Wu; Zifeng Huang; Xiaoqian Hao; YiChun Ji; Dongfeng Chen; Meiling Zhu
Journal:  Front Aging Neurosci       Date:  2021-11-29       Impact factor: 5.750

4.  Uric Acid Potential Role in Systemic Inflammation and Negative Symptoms After Acute Antipsychotic Treatment in Schizophrenia.

Authors:  Milica M Borovcanin; Slavica Minic Janicijevic; Natasa R Mijailovic; Ivan P Jovanovic; Nebojsa N Arsenijevic; Katarina Vesic
Journal:  Front Psychiatry       Date:  2022-02-14       Impact factor: 4.157

5.  Chronic Cerebral Hypoperfusion Aggravates Parkinson's Disease Dementia-Like Symptoms and Pathology in 6-OHDA-Lesioned Rat through Interfering with Sphingolipid Metabolism.

Authors:  Yaohua Fan; Mengzhu Li; Chunxiao Wu; Yubiao Wu; Jiajun Han; Peipei Wu; Zifeng Huang; Qizhang Wang; Lijun Zhao; Dongfeng Chen; Meiling Zhu
Journal:  Oxid Med Cell Longev       Date:  2022-08-08       Impact factor: 7.310

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.